(Q39455228)

12 September 2017

title

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial (English)

1 reference

12 September 2017

1 reference

7

Mathias Uhlén

1 reference

12 September 2017

Signe Borgquist

11

0 references

Karin Jirström

4

object named as

Karin Jirström

1 reference

12 September 2017

Olöf Bjarnadottir

1

1 reference

12 September 2017

Quinci Romero

2

1 reference

12 September 2017

Pär-Ola Bendahl

3

1 reference

12 September 2017

Lisa Rydén

5

1 reference

12 September 2017

Niklas Loman

6

1 reference

12 September 2017

Henrik Johannesson

8

1 reference

12 September 2017

Carsten Rose

9

1 reference

12 September 2017

Dorthe Grabau

10

1 reference

12 September 2017

language of work or name

English

0 references

publication date

8 March 2013

1 reference

Breast Cancer Research and Treatment

12 September 2017

published in

1 reference

12 September 2017

volume

138

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

499-508

1 reference

Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Statin use and breast cancer risk in a large population-based setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Breast cancer growth prevention by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Statin use and breast cancer: prospective results from the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Dysregulation of the mevalonate pathway promotes transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Statins and cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Statins and cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Molecular mechanisms involved in farnesol-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Isoprenoids as mediators of the biological effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Statin use and reduced cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Novel aspects of mevalonate pathway inhibitors as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

Statin use and risk of breast cancer: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2473-6

10.1007/S10549-013-2473-6

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference